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Abstract Plasma phospholipid transfer protein (PLTP)
transfers phospholipids between lipoproteins and mediates
HDL conversion. PLTP-overexpressing mice have increased
atherosclerosis. However, mice do not express cholesteryl
ester transfer protein (CETP), which is involved in the same
metabolic pathways as PLTP. Therefore, we studied athero-
 
sclerosis in heterozygous LDL receptor-deficient (LDLR
 

 
/
 

 
)
mice expressing both human CETP and human PLTP. We
used two transgenic lines with moderately and highly ele-
 
vated plasma PLTP activity. In LDLR
 

 
/
 

 
/huCETPtg mice,
cholesterol is present in both LDL and HDL. Both are de-
 
creased in LDLR
 

 
/
 

 
/huCETPtg/huPLTPtg mice (
 

 
50%).
An atherogenic diet resulted in high levels of VLDL
 

 
LDL
cholesterol. PLTP expression caused a strong PLTP dose-
dependent decrease in VLDL and LDL cholesterol (
 

 
26%
and 
 

 
69%) and a decrease in HDL cholesterol (
 

 
70%).
Surprisingly, atherosclerosis was increased in the two trans-
genic lines with moderately and highly elevated plasma
PLTP activity (1.9-fold and 4.4-fold, respectively), indicat-
ing that the adverse effect of the reduction in plasma HDL
outweighs the beneficial effect of the reduction in apolipo-
protein B (apoB)-containing lipoproteins. The activities of
the antiatherogenic enzymes paraoxonase and platelet-acti-
vating factor acetyl hydrolase were both PLTP dose-depen-
 
dently reduced (
 

 
 
 

 
33% and 
 

 
65%, respectively).  We
conclude that expression of PLTP in this animal model re-
sults in increased atherosclerosis in spite of reduced apoB-
containing lipoproteins, by reduction of HDL and of HDL-
associated antioxidant enzyme activities.
 
—Lie, J., R. de
Crom, T. van Gent, R. van Haperen, L. Scheek, F. Sadeghi-
Niaraki, and A. van Tol.
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Plasma levels of HDL are inversely correlated with the
risk for development of atherosclerosis (1). HDLs are con-
sidered to have various atheroprotective effects, including
anti-inflammatory and antioxidant properties and the po-
tential to transport excess cholesterol from peripheral cells
to the liver for degradation and excretion via the bile (1–4).
Phospholipid transfer protein (PLTP) plays several key
roles in HDL metabolism (5–8). PLTP facilitates the trans-
fer of phospholipids, 
 

 
-tocopherol, and possibly unes-
terified cholesterol from triglyceride-rich lipoproteins to
HDL particles during lipolysis (9, 10). PLTP is able to
modulate HDL size and composition (11–13) and may
also be involved in HDL cellular-mediated efflux of phos-
pholipids and cholesterol (14).
Elevation of PLTP in transgenic mice results in a PLTP
dose-dependent decrease in plasma HDL levels, coincid-
ing with an increased susceptibility to diet-induced athero-
sclerosis (15). These results are in agreement with the pre-
vious study by Jiang et al. (16), who demonstrated that
PLTP-deficient mice are less prone to atherosclerosis.
However, the explanations for the results were different in
these cases; the changes in atherosusceptibility in PLTP-
deficient mice were explained by a decrease of hepatic
VLDL secretion, not by an HDL effect. Elevation of PLTP
results in a stimulation of VLDL secretion (17), but this ef-
fect was found to be PLTP dose independent. Therefore,
it was considered to be a contributor to but not the main
cause for the atherogenic effect of elevated PLTP (15).
Mice do not have cholesteryl ester transfer protein
(CETP). Thus, the previously described genetically modi-
fied mice might be considered poor models in which to
study the relation between PLTP and atherosclerosis, inas-
 
Abbreviations: apoB, apolipoprotein B; CETP, cholesteryl ester
transfer protein; HFHC, high fat, high cholesterol; LDLR, LDL recep-
tor; PAF-AH, platelet-activating factor acetyl hydrolase; PLTP, phospho-
lipid transfer protein; PON, paraoxonase.
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much as CETP is thought to be critically involved in athero-
genesis (18). Moreover, although PLTP and CETP function
independently (19, 20), CETP affects the metabolism of
both HDL and apolipoprotein B (apoB)-containing lipo-
proteins (18). Therefore, we decided to study the effect of
elevated PLTP activity on atherosclerosis using mice geneti-
cally modified to express CETP. We found that also in this
context, PLTP increases the susceptibility to diet-induced
atherosclerosis. Surprisingly, this effect was found in spite
of lowered levels of apoB-containing lipoproteins.
MATERIALS AND METHODS
 
Animals
 
Human PLTP transgenic mice were obtained as described pre-
viously (15). In this study, we used mice with moderately and
highly elevated PLTP activity (lines huPLTPtgP4 and huPLTPtgA2,
respectively). LDL receptor (LDLR) knockout mice were pur-
chased from Jackson Laboratory. The huCETPtg mice were
kindly provided by Dr. A. R. Tall (Columbia University, New
York). All mice were in the C57BL/6J background. We created
LDLR
 

 
/
 

 
/huCETPtg mice, which were used as control mice. By
crossbreeding these mice with the PLTP transgenic mouse lines
expressing various levels of PLTP, we obtained LDLR
 

 
/
 

 
/hu-
CETPtg/huPLTPtgP4 and LDLR
 

 
/
 

 
/huCETPtg/huPLTPtgA2
mice. Male mice were used in all experiments.
After weaning, animals were kept on a standard chow diet
(Hope Farms, The Netherlands). At 4 months of age, all groups
of mice were put on a high-fat, high-cholesterol (HFHC) diet for
14 weeks, which contained 40% (w/w) sucrose, 15% (w/w) fat,
and 1% (w/w) cholesterol, and 0.5% (w/w) cholate to increase
uptake of fat and cholesterol, leading to high plasma cholesterol
levels. Animals had free access to water and food. After animals
were fasted overnight, blood samples were collected from the or-
bital plexus by using Vitrex™ sodium-heparinized micropipettes
(80 IU) (Modulohm A/S, Copenhagen, Denmark) and immedi-
ately stored on ice. Blood was centrifuged at 2,700 rpm for 15
min at 4
 

 
C. Plasma was either used immediately or stored in
small aliquots at 
 

 
80
 

 
C until analysis. All experiments con-
formed to national and institutional guidelines.
 
Separation of plasma lipoproteins by gel filtration
 
Plasma from transgenic mice was analyzed by gel filtration on
two HR10/30 fast-protein liquid chromatography columns in tan-
dem (Superdex 200 prepgrade, Superose 6 prepgrade, Pharmacia
Biotech, Uppsala, Sweden). The columns were equilibrated with 2
mM NaH
 
2
 
PO
 
4
 
/Na
 
2
 
HPO
 
4
 
, pH 7.4 [containing 0.9% NaCl (w/v),
0.02% NaN
 
3
 
 (w/v), and 5 mM EDTA]. Combined plasma sam-
ples were passed through 0.45 
 

 
m filters from Millipore S.A.
(Molsheim, France), and 0.5 ml was subjected to gel filtration. The
columns were run at 4
 

 
C with a flow rate of 0.1 ml/min. Fractions
of 0.8 ml were collected. Recoveries were 
 

 
90% for all analyses.
 
Separation of plasma lipoproteins by density 
gradient centrifugation
 
Lipoprotein fractions were obtained by density gradient ultra-
centrifugation of plasma samples in a Beckman SW60 Ti rotor
(36,500 rpm, 21 h 12 min, 12
 

 
C) (21). Alternatively, HDL and
VLDL
 

 
LDL lipoprotein fractions were obtained by density gra-
dient ultracentrifugation of plasma samples in a Beckman 42.2
Ti rotor (42,000 rpm, 3 h 12 min, 12
 

 
C) at d 
 

 
 1.063 g/ml. The
lipoprotein fractions were collected by tube slicing.
 
Quantification of cholesterol
 
Cholesterol was determined enzymatically with the Free Cho-
lesterol C kit no. 274-47109 (WAKO, Neuss, Germany) after hy-
drolysis of cholesteryl esters with cholesterol esterase from 
 
Can-
dida cylindracea
 
 (Boehringer, Mannheim, Germany).
 
Plasma activity assays
 
CETP and PLTP activity assays were performed as described pre-
viously (22). The activities are expressed as arbitrary units (AUs); 1
AU is the activity found in human reference pool plasma. The ac-
tivities are: CETP, 216 nmol/ml/h; PLTP, 14 
 

 
mol/ml/h.
Paraoxonase (PON) activity toward paraoxon was quantified
spectrophotometrically essentially as described (23). In short,
10–20 
 

 
l of serum or heparin-plasma was added to 1 ml incuba-
tion medium with 50 mM Tris-HCL buffer (pH 8.0) containing 1
mM CaCl
 
2
 
 and 6.0 mM paraoxon. The reaction was monitored
for up to 30 min at 25
 

 
C by measuring the appearance of 
 
p
 
-nitro-
phenol at 412 nm in a CARY 1E UV visible spectrophotometer.
PON activity is expressed as U/ml.
Platelet-activating factor acetyl hydrolase (PAF-AH) was deter-
mined as described by Tselepis et al. (24), using 2-[
 
3
 
H-acetyl]PAF
as substrate. In short, 80 nmol of substrate (final concentration
0.33 mM) was incubated with 10 
 

 
l diluted (10-fold) plasma sam-
ples in incubation medium (total volume 0.24 ml) with 0.1 M
Tris-HCl buffer, pH 7.4, containing 0.9% NaCl and 1 mM EDTA.
After incubation for 20 min at 37
 

 
C, the reaction was stopped on
ice and 300 
 

 
l CHCl
 
3
 
 and 600 
 

 
l methanol were added. After
mixing, another 300 
 

 
l of CHCl
 
3
 
 was added with 300 
 

 
l 0.9%
NaCl, pH 2.0. After mixing again, phase separation was obtained
by centrifugation for 30 min. Seven hundred microliters of the
upper layer was used for counting radioactive acetic acid. PAF-
AH activity is expressed as nmol/min/ml plasma.
 
Histological assessment of atherosclerosis
 
After 14 weeks of feeding the HFHC diet, mice were sacrificed
following collection of blood as described above. The hearts
were dissected, stored in phosphate-buffered 4% formaldehyde
until processing, and embedded in paraffin. Serial cross sections
of 5 
 

 
m throughout the aortic valve area were used for histologi-
cal analysis. Sections were stained with hematoxylin and eosin.
Five sections per mouse, with intervals of 60 
 

 
m, were used for
quantification of atherosclerotic lesion areas as described previ-
ously (15). To evaluate whether PLTP has an effect on accumula-
tion of free cholesterol in atherosclerotic lesions, the number of
sections containing free cholesterol clefts in each group was
counted as described by Delsing et al. (25).
 
Statistical analysis
 
Data are expressed as means 
 
	
 
 SE. Differences were analyzed
by two-sample Wilcoxon rank sum tests by using Intercooled
Stata 6.0 software (Stata Corporation, College Station, TX).
 
RESULTS
 
Elevation of PLTP activity lowers plasma cholesterol
 
Plasma levels of total cholesterol, VLDL
 

 
LDL cho-
lesterol, and HDL cholesterol were measured in
LDLR
 

 
/
 

 
/huCETPtg, LDLR
 

 
/
 

 
/huCETPtg/huPLTPtgP4,
and LDLR
 

 
/
 

 
/huCETPtg/huPLTPtgA2 mice, respectively
(
 
Table 1
 
). The PLTP-overexpressing mouse lines were
compared with LDLR
 

 
/
 

 
/huCETPtg mice, which are re-
ferred to as control mice throughout the present study.
Overexpression of PLTP resulted in a dramatic reduction
of plasma levels of total cholesterol (
 

 
50% and 
 

 
70%
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in LDLR
 

 
/
 

 
/huCETPtg/huPLTPtgP4 and LDLR
 

 
/
 

 
/hu-
CETPtg/huPLTPtgA2 mice, respectively, compared with
control). This reduction in plasma cholesterol was found
in both VLDL
 

 
LDL and in HDL lipoprotein classes. In a
chow diet, the majority of the plasma cholesterol is in
HDL, in which class the strongest reduction in cholesterol
was found.
 
Overexpression of PLTP increases susceptibilty 
to atherosclerosis
 
After the animals had been fed an HFHC diet for 14
weeks, the areas of the atherosclerotic lesions were quanti-
fied in cross sections of the aortic valves from individual
mice. As shown in 
 
Fig. 1A
 
, atherosclerosis was more severe
in LDLR
 

 
/
 

 
/huCETPtg/huPLTPtgP4 mice as compared
 
TABLE 1. Plasma cholesterol levels in mice fed normal chow diet
 
Transgenic 
Mouse Line
LDLR
 

 
/
 

 
/huCETPtg 
(n 
 

 
 19)
LDLR
 

 
/
 

 
/huCETPtg/huPLTPtgP4 
(n 
 

 
 16–20)
LDLR
 

 
/
 

 
/huCETPtg/huPLTPtgA2 
(n 
 

 
 16–18)
 
mM
 
TC 2.7 
 
	
 
 0.1 1.4 
 
	
 
 0.1
 
a
 
0.8 
 
	
 
 0.1
 
a
 
HDL-TC 1.7 
 
	
 
 0.1 0.7 
 
	
 
 0.1
 
a
 
0.04 
 
	
 
 0.01
 
a
 
VLDL
 

 
LDL-TC 0.8 
 
	
 
 0.1 0.4 
 
	
 
 0.1
 
a
 
0.44 
 
	
 
 0.06
 
a
 
CETP, cholesteryl ester transfer protein; PLTP, phospholipid transfer protein; TC, total cholesterol.
 
a
 
 Significantly different from LDLR
 

 
/
 

 
/huCETPtg, P 
 0.001.
Fig. 1. Atherosclerosis in transgenic mice after 14 weeks of a high-fat, high-cholesterol (HFHC) diet. Mice (n  9–13 per group) were sac-
rificed, and aortas were removed and atherosclerotic lesion areas in the aortic roots were determined as described in Materials and Meth-
ods. A: Aortic valve lesion areas; B: percentage of sections containing free cholesterol clefts in the aortic lesions; C: representative lesion ar-
eas of LDLR//huCETPtg, LDLR//huCETPtg/huPLTPtgP4, and LDLR//huCETPtg/huPLTPtgA2 mice. Cholesterol clefts are
particularly conspicuous in the lowest panel. Values represent means 	 SE. * P 
 0.05 compared with LDLR//huCETPtg mice.
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with control mice, while a further increase was found in
LDLR//huCETPtg/huPLTPtgA2 mice.
We also evaluated whether PLTP overexpression in-
creased the number of sections containing cholesterol
clefts (Fig. 1B). In control mice, cholesterol clefts were
not observed. However, in mice overexpressing human
PLTP cholesterol, clefts were present. Moreover, athero-
sclerotic lesions from LDLR//huCETPtg/huPLTPtgA2
mice showed more cholesterol clefts than those from
LDLR//huCETPtg/huPLTPtgP4 mice (P  0.05). Fig.
1C shows representative photographs of the atheroscle-
rotic lesions from mice of the various genotypes.
PLTP expression reduces 
diet-induced hypercholesterolemia
To determine why LDLR//huCETPtg/huPLTPtgP4
and LDLR//huCETPtg/huPLTPtgA2 mice have more
atherosclerosis than do control mice, we analyzed the levels
of plasma cholesterol after feeding the animals an HFHC
cholesterol diet for 14 weeks (Table 2). As expected, the
diet resulted in a strong increase of the plasma levels of to-
tal cholesterol in all three genotypes (compare Tables 1
and 2). However, overexpression of PLTP reduced total
cholesterol in plasma compared with control mice. As a
consequence of the diet, the bulk of the plasma choles-
terol was in VLDLLDL in all three genotypes analyzed.
A PLTP dose-dependent decrease in VLDLLDL cholesterol
was found in PLTP-overexpressing mice compared with
control mice (26% and 69% in LDLR//huCETPtg/
huPLTPtgP4 and LDLR//huCETPtg/huPLTPtgA2 mice,
respectively). HDL cholesterol was also strongly reduced
in the PLTP-overexpressing animals (70% in both geno-
types compared with control mice).
To examine the effects on lipoprotein classes in more de-
tail, plasma samples from the various transgenic mouse
lines were analyzed by gel filtration chromatography (Fig.
2). The HFHC diet resulted in an increase of total plasma
cholesterol in all lipoprotein fractions of all transgenic
mouse lines compared with the cholesterol profiles found
on chow diet (results not shown). The HFHC diet also in-
duced a strong shift of the cholesterol profiles to the more
atherogenic lipoproteins, intermediate density lipoproteins
and VLDLs. The effect of PLTP expression was a decrease
in cholesterol in these lipoprotein fractions. The biggest ef-
fect was found in the mice with the highest plasma PLTP ac-
tivity level, i.e., the LDLR//huCETPtg/huPLTPtgA2
mice. HDL cholesterol was almost absent after feeding the
diet for 14 weeks in both PLTP-expressing lines (Fig. 2).
Therefore, overexpression of PLTP in the presence of
CETP results in an elevation of diet-induced atherosclero-
sis in spite of markedly reduced levels of apoB-containing
lipoproteins. This suggests that the effect on atherosclero-
sis is caused by the strong reduction in HDL. How-
ever, LDLR//huCETPtg/huPLTPtgP4 and LDLR//
huCETPtg/huPLTPtgA2 mice hardly differ in HDL
cholesterol levels after the animals have been fed the
HFHC diet for 14 weeks, while the atherosclerotic lesion
size is considerably higher in the LDLR//huCETPtg/hu-
PLTPtgA2 mice. Therefore, we proceeded to examine
HDL-associated lipid transfer and enzymatic activities.
CETP and PLTP activities
After the animals had been fed an HFHC diet for 14
weeks, CETP activities were slightly decreased in PLTP-
overexpressing mice compared with control mice (Fig.
3A). However, no difference was found in plasma CETP
activity between mice with moderate and those with high
PLTP expression. Differences in plasma PLTP activity lev-
els were maintained after the diet period (Fig. 3B).
Effect of PLTP overexpression on PON 
and PAF-AH activities
PON and PAF-AH are HDL-associated enzymes that
may have antiatherogenic properties (26, 27). Because
PLTP overexpression lowers the plasma HDL concentra-
tions in our mice, we examined whether this might affect
TABLE 2. Plasma cholesterol levels in mice fed an HFHC diet
Transgenic Mouse 
Line
LDLR//huCETPtg 
(n  17)
LDLR//huCETPtg/huPLTPtgP4 
(n  18)
LDLR//huCETPtg/huPLTPtgA2 
(n  13–17)
mM
TC 11.3 	 0.8 8.3 	 0.6a 5.5 	 1.1b
HDL-TC 1.0 	 0.1 0.3 	 0.02b 0.3 	 0.1b
VLDL  LDL-TC 10.8 	 0.7 8.0 	 0.7a 3.4 	 0.3b
HFHC, high fat, high cholesterol.
a Significantly different from LDLR//huCETPtg, P 
 0.05.
b Significantly different from LDLR//huCETPtg, P 
 0.001.
Fig. 2. Distribution of lipoproteins in plasma from transgenic
mice. Equal amounts of plasma from transgenic mice (n  16–20)
fed an HFHC diet for 14 weeks were pooled and subjected to gel fil-
tration on Superose 6 and Superdex 200 columns connected in tan-
dem as described in Materials and Methods. Fractions 1–5 contain
VLDL, fractions 6–11 contain LDL, fractions 12–20 contain HDL,
and fractions 21–25 contain albumin. Circles, LDLR//huCETPtg
mice; triangles, LDLR//huCETPtg/huPLTPtgP4 mice; squares,
LDLR//huCETPtg/huPLTPtgA2 mice.
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these enzymes as well (Fig. 4). Indeed, we found that
PLTP overexpression was associated with decreased activi-
ties of both PON and PAF-AH. In LDLR//huCETPtg/
huPLTPtgP4 and LDLR//huCETPtg/huPLTPtgA2 mice,
respectively, PON activity was 33% and 60% lower com-
pared with control mice (Fig. 4A). The reduction in PAF-
AH activity was 33% and 70%, respectively (Fig. 4B). The
difference in activity between the two lines of PLTP-
expressing mice was statistically significant for both enzymes,
suggesting PLTP dose-dependent lowering effects.
DISCUSSION
In the present study, we corroborated our previous find-
ing that elevated PLTP activity in plasma results in increased
atherosclerosis in mice (15). However, the crucial difference
between this study and the previous study is that we now
used transgenic mouse models that express CETP in addi-
tion to PLTP. Increased CETP activity has been found to re-
sult in increased atherosclerosis in mice (28, 29), rats (30),
and rabbits (31). We demonstrated that variations in PLTP
activity modulate the susceptibility to diet-induced athero-
sclerosis in addition to the CETP effect. Surprisingly, the
atherogenic effect of PLTP was found despite a decrease of
plasma cholesterol in apoB-containing lipoproteins. Plasma
levels of HDL were also lower in PLTP-overexpressing mice.
This is in agreement with results reported previously in
other mouse models with elevated PLTP activity from our
laboratory as well as other laboratories (15, 32, 33). In the
present study, we found that the decrease in plasma choles-
terol in both lipoprotein classes studied, i.e., apoB-contain-
ing lipoproteins and HDL, persist after the animals have
been fed the HFHC diet for 14 weeks. These findings sug-
gest that the reduction in plasma HDL affects the develop-
ment of atherosclerosis to a greater extent than does the re-
duction in apoB-containing lipoproteins.
Fig. 3. Cholesteryl ester transfer protein (CETP) and phospho-
lipid transfer protein (PLTP) activities in plasma from transgenic
mice. Plasma samples from the various transgenic mouse lines were
analyzed for CETP (A) and PLTP (B) activities as described in Ma-
terials and Methods after the mice had been fed an HFHC diet for
14 weeks. Values shown are means 	 SE obtained from 13 mice
per group. * P 
 0.05 compared with LDLR//huCETPtg mice.
Fig. 4. Antioxidant enzyme activities in plasma from transgenic
mice. Plasma samples from the various transgenic mouse lines were
analyzed for paraoxonase (A) and platelet-activating factor acetyl
hydrolase (B) activities as described in Materials and Methods. Val-
ues shown are means 	 SE obtained from 4–7 mice per group.
* P 
 0.05 compared with LDLR//huCETPtg mice; † P 
 0.05
compared with LDLR//huCETPtg/huPLTPtgP4 mice.
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We used two lines of transgenic mice overexpress-
ing human PLTP to different levels. The LDLR//hu-
CETPtg/huPLTPtgA2 mice have the highest level of PLTP
activity and also have the highest level of atherosclerosis.
However, the levels of plasma HDL cholesterol are similar
between the two lines at the end of the 14 week period of
HFHC diet. On the other hand, on a chow diet, the
LDLR//huCETPtg/huPLTPtgA2 mice have lower lev-
els of plasma HDL cholesterol than the LDLR//hu-
CETPtg/huPLTPtgP4 mice. Therefore, the variation in
atherosclerosis could be caused by the difference in HDL
cholesterol, even though this equals out during the diet
period. The presence of a larger number of cholesterol
clefts in LDLR//huCETPtg/huPLTPtgA2 mice com-
pared with LDLR//huCETPtg/huPLTPtgP4 mice is in-
dicative of a less-efficient removal of cholesterol from the
atherosclerotic lesions by reverse cholesterol transport, al-
lowing the formation of extracellular cholesterol crystal-
line deposits, which are inert and cannot be mobilized
(34). However, there could also be a qualitative differ-
ence between the HDL from the LDLR//huCETPtg/
huPLTPtgP4 and that from the LDLR//huCETPtg/
huPLTPtgA2 mice. Therefore, we analyzed the activity of
transfer proteins and enzymes that have been found to
be associated with HDL in various mouse models (17,
35, 36).
A small but statistically significant decrease in CETP ac-
tivity was found in the mice overexpressing PLTP. This is
in agreement with previous findings from our laboratory
(20) and may be caused by the drop in HDL levels caused
by PLTP expression, inasmuch as HDL is the carrier of
CETP. As outlined above, CETP is atherogenic in various
animal models. Therefore, the small decrease in CETP
activity cannot explain the increase in atherosclerosis
found in PLTP-overexpressing animals. Moreover, CETP
activity is not different between LDLR//huCETPtg/hu-
PLTPtgP4 and LDLR//huCETPtg/huPLTPtgA2 mice.
As expected, the mice have different levels of plasma
PLTP activity, which persist at the end of the diet period.
In addition, the activities of PON and PAF-AH were
found to be decreased in PLTP-overexpressing mice. Both
enzymatic activities are lower in LDLR//huCETPtg/
huPLTPtgA2 mice than in LDLR//huCETPtg/hu-
PLTPtgP4 mice. Elevation of the activity of either PON
(37) or PAF-AH (38) results in decreased atherosclerosis
in mice. Moreover, PON-deficient mice have increased
atherosclerosis (39), while decreased activities of both en-
zymes have been found in mouse models susceptible to
atherosclerosis (36). It is likely that the decrease in PON
and PAF-AH activities is related to the decrease in HDL,
because in mice, these enzymes are mainly associated with
HDL (35, 36), even in animals with extremely elevated
plasma cholesterol in apoB-containing lipoproteins.
At present, it is not clear why overexpression of PLTP
results in a decrease in VLDLLDL cholesterol in plasma
in LDLR//huCETPtg/huPLTPtgP4 and LDLR//
huCETPtg/huPLTPtgA2 mice. In the absence of CETP,
PLTP overexpression does not affect VLDLLDL choles-
terol levels (15). On the other hand, in mice that have no
mutations in the LDLR (LDLR/), VLDLLDL choles-
terol levels in huCETPtg mice and in huCETPtg/hu-
PLTPtg mice are similar (20). Therefore, the LDLR seems
to play a critical role in the effect of PLTP in CETP-trans-
genic mice. An alternative explanation is that the effect of
PLTP on apoB-containing lipoproteins exists only above
a certain threshold level of these lipoproteins. Both
LDLR/ mice (15, 40) and CETP transgenic mice (20,
29) show an increase in plasma levels of apoB-containing
lipoproteins. Consequently, the levels of these lipopro-
teins are higher in the mice analyzed in the present study
than in those analyzed in the earlier studies.
PLTP deficiency has been shown to increase the vitamin
E content of VLDL and LDL, thereby protecting these
lipoproteins from oxidation (41). Conversely, elevated
PLTP expression might result in decreased vitamin E in
VLDLLDL and thus in a higher susceptibility to oxida-
tive modification of these lipoproteins, resulting in a
more rapid removal from the plasma compartment. This
mechanism could contribute to the atherogenicity of PLTP
overexpression, despite a decrease in plasma VLDLLDL
cholesterol concentration.
In conclusion, elevated expression of PLTP results in
decreased plasma cholesterol in both atherogenic apoB-
containing lipoproteins and antiatherogenic HDL. Inas-
much as the susceptibility to atherosclerosis is increased in
a PLTP dose-dependent fashion, the effect on HDL appar-
ently outweighs the effect on apoB-containing lipopro-
teins. The mechanism may include various atheroprotec-
tive properties of HDL, including the involvement in
reverse cholesterol transport and the association with anti-
oxidant enzymes.
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